OBJECTIVE: Systemic sclerosis (SSc) has the highest case-specific mortality of any rheumatic disease, and no effective therapy is available. A clear manifestation of SSc is the presence of autoantibodies. However, the origin of autoantibody-producing B lymphocytes, their mechanisms of activation and autoantibody production, and their role remain unclear. This study was undertaken to identify mechanisms that contribute to pathogenic B cell generation and involvement in SSc and to assess the altered distribution and function of B cells in SSc patients. METHODS: Multicolor flow cytometry was performed to determine B cell subset distribution, cytokine production, and tolerance induction in SSc patients and healthy controls. Cytokine production following stimulation of the cells ex vivo was determined by multiplex assay. RESULTS: A range of defects in B lymphocyte tolerance and cytokine production in SSc were noted. There was evidence of altered distribution of transitional B cell subsets, increased production of interleukin-6 (IL-6) and IL-8, and defective tolerance induction in SSc B cells. In addition, B cells from SSc patients had a reduced ability to produce IL-10 when stimulated through innate immune pathways. In contrast to healthy individuals, tolerance checkpoints in SSc patients failed to suppress the emergence of B cells that produce autoantibodies with specificity to the Scl-70 antigen, which is strongly associated with SSc. These defects were paralleled by altered intracellular signaling and apoptosis following B cell receptor engagement. CONCLUSION: Our findings provide new insights into mechanisms underlying defective B lymphocyte responses in patients with SSc and their contribution to disease.
OBJECTIVE: Systemic sclerosis (SSc) has the highest case-specific mortality of any rheumatic disease, and no effective therapy is available. A clear manifestation of SSc is the presence of autoantibodies. However, the origin of autoantibody-producing B lymphocytes, their mechanisms of activation and autoantibody production, and their role remain unclear. This study was undertaken to identify mechanisms that contribute to pathogenic B cell generation and involvement in SSc and to assess the altered distribution and function of B cells in SSc patients. METHODS: Multicolor flow cytometry was performed to determine B cell subset distribution, cytokine production, and tolerance induction in SSc patients and healthy controls. Cytokine production following stimulation of the cells ex vivo was determined by multiplex assay. RESULTS: A range of defects in B lymphocyte tolerance and cytokine production in SSc were noted. There was evidence of altered distribution of transitional B cell subsets, increased production of interleukin-6 (IL-6) and IL-8, and defective tolerance induction in SSc B cells. In addition, B cells from SSc patients had a reduced ability to produce IL-10 when stimulated through innate immune pathways. In contrast to healthy individuals, tolerance checkpoints in SSc patients failed to suppress the emergence of B cells that produce autoantibodies with specificity to the Scl-70 antigen, which is strongly associated with SSc. These defects were paralleled by altered intracellular signaling and apoptosis following B cell receptor engagement. CONCLUSION: Our findings provide new insights into mechanisms underlying defective B lymphocyte responses in patients with SSc and their contribution to disease.
Authors: Yannick Dieudonné; Vincent Gies; Aurélien Guffroy; Céline Keime; Anna K Bird; Jane Liesveld; Jennifer L Barnas; Vincent Poindron; Nawal Douiri; Pauline Soulas-Sprauel; Thierry Martin; Eric Meffre; Jennifer H Anolik; Anne-Sophie Korganow Journal: J Autoimmun Date: 2019-05-10 Impact factor: 7.094
Authors: Jacob Paiano; Micah Harland; Michael G Strainic; John Nedrud; Wasim Hussain; M Edward Medof Journal: J Immunol Date: 2019-06-19 Impact factor: 5.422
Authors: K Higashioka; Y Kikushige; M Ayano; Y Kimoto; H Mitoma; M Kikukawa; M Akahoshi; Y Arinobu; T Horiuchi; K Akashi; H Niiro Journal: Clin Exp Immunol Date: 2020-07-14 Impact factor: 4.330
Authors: Michael Gernert; Hans-Peter Tony; Eva Christina Schwaneck; Ottar Gadeholt; Marc Schmalzing Journal: Arthritis Res Ther Date: 2019-04-29 Impact factor: 5.156
Authors: Salome Glauzy; Brennan Olson; Christopher K May; Daniele Parisi; Christopher Massad; James E Hansen; Changwan Ryu; Erica L Herzog; Eric Meffre Journal: Arthritis Rheumatol Date: 2021-12-16 Impact factor: 15.483